Therefore, a multifunctional oxygen delivery nanoplatform was rationally constructed based on oxygen-saturated perfluorohexane (PFH) core liposomes, with the CXCR4 antagonist LFC131 peptide modified on the surface to simultaneously deliver sorafenib and the CSF1/CSF1R inhibitor PLX3397 (named PFH@LSLP) for the treatment of HCC resistant to sorafenib (18). Here, CXCR4 is linked to hepatocellular carcinoma.